Fox Run Management’s Puma Biotechnology PBYI Stock Holding History

Fox Run Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,047	Closed	-$130K	–	493
2019 Q3	$130K	Buy	+12,047	New	+$130K	0.12%	329
2019 Q2	–	Sell	-15,031	Closed	-$583K	–	578
2019 Q1	$583K	Sell	15,031 -4,257	-22%	-$130K	0.33%	75
2018 Q4	$393K	Buy	19,288 +7,225	+60%	+$217K	0.21%	186
2018 Q3	$553K	Buy	+12,063	New	+$582K	0.24%	143
2017 Q4	–	Sell	-2,800	Closed	-$335K	–	830
2017 Q3	$335K	Buy	2,800 +200	+8%	+$18.6K	0.09%	442
2017 Q2	$227K	Buy	+2,600	New	+$145K	0.08%	507
2017 Q1	–	Sell	-21,300	Closed	-$654K	–	707
2016 Q4	$654K	Buy	+21,300	New	+$921K	0.34%	56
2016 Q2	–	Sell	-13,100	Closed	-$385K	–	638
2016 Q1	$385K	Buy	+13,100	New	+$592K	0.26%	146

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fox Run Management's PBYI Position: Q4 2019 in Review

Fox Run Management sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 12,047 shares — an estimated $130K sold.

Fox Run Management first reported a position in PBYI in Q1 2016 and held it in 8 quarters. The position peaked at $654K in Q4 2016. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

Fox Run Management reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
Fox Run Management sold 12,047 Puma Biotechnology shares in Q4 2019, an estimated $130K.
Fox Run Management first reported a position in Puma Biotechnology in Q1 2016 and held it in 8 quarters.
Fox Run Management's Puma Biotechnology position peaked at $654K in Q4 2016.
133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Fox Run Management's 13F filing for Q4 2019, filed 14 Feb 2020.